
The Food and Drug Administration (FDA) recently announced authorization of Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on intervention by an operator.
One supervising phlebotomist can oversee up to three Aletta devices at the same time, according to the authorization, which also specifies that Aletta should be used with adults in outpatient settings.
After the phlebotomist initiates each session, the Aletta autonomously handles the blood draw. It uses near-infrared light and Doppler ultrasound to locate a suitable vein and distinguish it from arteries. If it finds no appropriate vein, the device will not attempt the procedure.
After finding a suitable vein, Aletta applies a tourniquet, prepares the skin, inserts and disposes the needle, changes collection tubes, and applies a bandage. The supervising phlebotomist confirms that collection tubes are filled in the correct order and verifies that all tubes are adequately full following the procedure.
The device continuously applies disinfectant to the skin during the ultrasound scan. A trained professional cleans the device between patients.
The device may help address the current phlebotomist shortage in the U.S., FDA said.
Amyloid pathology test earns FDA clearance
The Food and Drug Administration has cleared Roche’s Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test, the company recently announced.
The single-biomarker, blood-based test aids in the identification of amyloid pathology associated with Alzheimer’s disease in individuals 55 years and older with signs, symptoms, or complaints of cognitive decline. Elecsys pTau217 provides both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings.
Designed for use on the Roche cobas platform, the test may help clinicians assess the likelihood of amyloid pathology earlier and identify patients for additional evaluation or specialist referral, according to Roche.
The assay provides positive, intermediate, and negative result categories to support assessment of the likelihood of amyloid pathology. Results are interpreted in conjunction with clinical information and other relevant findings.
Companion diagnostic gets additional FDA approval for certain advanced breast cancers
Guardant Health has announced Food and Drug Administration (FDA) approval for its Guardant360 CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations before radiographic progression who may benefit from treatment with Etcamah (camizestrant).
The approval is based on data from the SERENA-6 clinical trial, which used circulating tumor DNA monitoring to detect emerging ESR1 resistance mutations before radiographic disease progression.
Study participants underwent serial testing with Guardant360 CDx every 3 months while receiving an aromatase inhibitor with a CDK4/6 inhibitor. Upon detection of an ESR1 mutation before radiographic progression, the researchers transitioned eligible patients to camizestrant-based treatment. Patients treated under this new paradigm experienced 74% longer median progression-free survival with a 47% reduction in risk of deterioration in global health status and quality of life, according to Guardant.
The trial demonstrated the clinical value of proactively identifying disease progression earlier than radiographic imaging and adapting therapy sooner in the course of disease. Historically, biomarker testing in advanced cancer most often occurred after clinical or radiographic progression, Guardant said.
This latest FDA approval for Guardant360 CDx marks its 29th CDx indication across multiple tumor types globally, the company added.
At-home flu and COVID-19 PCR test gets FDA clearance
Visby Medical recently received Food and Drug Administration (FDA) clearance for the Visby Medical Flu and COVID-19 Test. According to the company, this is the first multi-viral, over-the-counter PCR test to receive FDA authorization.
Designed for home use, the Visby Medical Flu and COVID-19 Test enables consumers to quickly test for COVID-19 and influenza A and B, providing a PCR result in 30 minutes. This, in turn, will help consumers to make faster decisions about care, including whether to seek antiviral treatment or connect with a telehealth provider.
Unlike antigen tests, PCR testing can detect infections earlier and at lower viral levels, making it the gold standard for diagnosing respiratory infections such as COVID-19 and influenza. Earlier detection of these viruses is especially important because antiviral medications such as Paxlovid and Tamiflu are most effective when started early in the course of infection.
WHO grants Emergency Use Listing for hemorrhagic fever panel test in response to Ebola
The World Health Organization (WHO) has granted an Emergency Use Listing (EUL) to Cepheid’s Xpert Hemorrhagic Fever Panel test to support the diagnostic response to the Ebola Bundibugyo virus (BDBV) outbreak in the Democratic Republic of Congo.
The Xpert Hemorrhagic Fever Panel test detects and identifies nucleic acids from the Ebola virus, as well as Crimean-Congo hemorrhagic fever virus, Marburg virus, and Lassa virus. The time to result is about 1 hour. The assay runs
on Cepheid's GeneXpert Dx systems, which are widely deployed across Africa.
The WHO declared the Congo outbreak a public health emergency of international concern on May 17. This EUL enables healthcare providers and public health authorities to leverage Cepheid’s rapid molecular testing technology to help identify suspected cases of BDBV and support timely outbreak containment efforts.
CE marking granted to syndromic tests for MERS-CoV and other respiratory viruses
bioMérieux has announced that its Biofire Respiratory 2.1 plus (RP2.1plus) Panel and Biofire Filmarray Pneumonia plus (PNplus) Panel have received CE marking in the European Union (EU) as Class D in vitro diagnostic devices.
This class of devices is subject to the most rigorous regulatory requirements under the EU In Vitro Diagnostic Regulation and is reserved for tests intended to detect pathogens that pose a high risk to public health. bioMérieux’s new tests were given this classification due to the inclusion of Middle East respiratory syndrome coronavirus (MERS-CoV) on both test menus, according to the company.
The Biofire RP2.1plus Panel provides broad syndromic testing for upper respiratory infections in about 45 minutes while the Biofire Filmarray PNplus Panel supports the diagnosis of lower respiratory tract infections by detecting a wide range of bacterial and viral pathogens as well as key antimicrobial resistance markers in about 1 hour. Both panels deliver actionable results that can help clinicians make informed decisions earlier in the patient's care pathway, according to bioMérieux.
